|
|
|
|
||
UBS - CELG: President’s Week Rx Solid for Otezla Otezla prescriptions: TRx +1%, NRx +4% w/w Scripts for Celgene's Otezla indicate TRx of 2,911 (up +1% w/w) and NRx of 1,633 (up +4% w/w). Assuming trends continue, we are tracking to $68m for 1Q15 US sales (FOA consensus $68m), but we acknowledge it is still early in the quarter. Below, we include a plot of the launch thus far for Otezla compared to the same period of the launch for Xeljanz. |
return to message board, top of board |